Phase 1 study of efatutazone, a novel oral peroxisome proliferator- activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer

Investigational New Drugs

Volumn 32, Issue 3, 2014, Pages 473-480

  Komatsu, Yoshito ^a   Yoshino, Takayuki ^b   Yamazaki, Kentaro ^c   Yuki, Satoshi ^a   Machida, Nozomu ^c   Sasaki, Takahide ^a,b   Hyodo, Ichinosuke ^d   Yachi, Yutaka ^e   Onuma, Hiroshi ^e   Ohtsu, Atsushi ^b  

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e DAIICHI SANKYO CO   (Japan)

Author keywords

Colorectal cancer; Efatutazone; FOLFIRI; Peroxisome proliferator activated receptor gamma

Indexed keywords

ADIPONECTIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATININE; EFATUTAZONE; FLUOROURACIL; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RETINOID X RECEPTOR; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOQ PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAMPTOTHECIN;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRONCHITIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPOALBUMINEMIA; HYPONATREMIA; INTERSTITIAL PNEUMONIA; JAPAN; JAPANESE (PEOPLE); LEUKOPENIA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; AGONISTS; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COLORECTAL NEOPLASMS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADIPONECTIN; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PPAR GAMMA; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84904609633     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0056-3     Document Type: Article

References (15)

1. Nemenoff RA, Weiser-Evans M, Winn RA (2008) Activation and molecular targets of peroxisome proliferator-activated receptor-gamma ligands in lung cancer. PPAR Res 2008:156875
2. Ondrey F (2009) Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 15:2-8
3. Burgermeister E, Seger R (2008) PPARgamma and MEK interactions in cancer. PPAR Res 2008:309469
4. Zou B, Qiao L, Wong BC (2009) Current understanding of the role of PPARγ in gastrointestinal cancers. PPAR Res 2009:816957
5. Skelhorne-Gross G, Nicol CJ (2012) The key to unlocking the chemotherapeutic potential of PPARgamma ligands: having the right combination. PPAR Res 2012:946943
6. Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM (2007) Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 11:395-406 (Pubitemid 46670076)
7. Tikoo K, Kumar P, Gupta J (2009) Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer 9:107
8. Chen L, Bush CR, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, Fields AP, Thompson EA (2006) RS5444, a novel PPARgamma agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells. Mol Cell Endocrinol 251:17-32 (Pubitemid 44250819)
9. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP, Smallridge RC (2006) Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25:2304 - 2317
10. Shimazaki N, Togashi N, Hanai M, Isoyama T, Wada K, Fujita T, Fujiwara K, Kurakata S (2008) Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Eur J Cancer 44:1734-1743
11. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S (2010) Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 101:1286-1291
12. Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, Zahir H, Copigneaux C, Liu K, Beckman RA, Demetri GD (2012) A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer 118:5403-5413
13. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237 (Pubitemid 41095086)
14. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomized phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853-860
15. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099 (Pubitemid 33643677)